Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Gains from Investment Securities (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Gains from Investment Securities for 13 consecutive years, with $154596.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Investment Securities changed N/A to $154596.0 in Q4 2025 year-over-year; TTM through Oct 2025 was $154596.0, a 64.26% decrease, with the full-year FY2025 number at $1.2 million, up 26.46% from a year prior.
  • Gains from Investment Securities was $154596.0 for Q4 2025 at PharmaCyte Biotech, up from $333.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $239189.0 in Q2 2023 to a low of -$1600.0 in Q1 2022.
  • A 5-year average of $102128.3 and a median of $127500.0 in 2024 define the central range for Gains from Investment Securities.
  • Peak YoY movement for Gains from Investment Securities: skyrocketed 10466.75% in 2023, then dropped 23.13% in 2024.
  • PharmaCyte Biotech's Gains from Investment Securities stood at $1600.0 in 2021, then skyrocketed by 2291.81% to $38269.0 in 2022, then surged by 525.02% to $239189.0 in 2023, then dropped by 19.14% to $193400.0 in 2024, then dropped by 20.06% to $154596.0 in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Gains from Investment Securities are $154596.0 (Q4 2025), $333.0 (Q3 2025), and $193400.0 (Q2 2024).